nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ABCB1—peripheral nervous system neoplasm	0.26	1	CbGaD
Tacrolimus—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0509	0.134	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0509	0.134	CbGbCtD
Tacrolimus—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.0382	0.1	CbGbCtD
Tacrolimus—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0267	0.0703	CbGbCtD
Tacrolimus—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0267	0.0703	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.0234	0.0615	CbGbCtD
Tacrolimus—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.0234	0.0615	CbGbCtD
Tacrolimus—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0185	0.0487	CbGbCtD
Tacrolimus—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0175	0.0461	CbGbCtD
Tacrolimus—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0161	0.0423	CbGbCtD
Tacrolimus—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.016	0.0421	CbGbCtD
Tacrolimus—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0149	0.0392	CbGbCtD
Tacrolimus—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0114	0.03	CbGbCtD
Tacrolimus—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0106	0.028	CbGbCtD
Tacrolimus—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0105	0.0275	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00713	0.0188	CbGbCtD
Tacrolimus—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00684	0.018	CbGbCtD
Tacrolimus—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00626	0.0165	CbGbCtD
Tacrolimus—PPP3CA—pons—peripheral nervous system neoplasm	0.0056	0.224	CbGeAlD
Tacrolimus—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00427	0.0112	CbGbCtD
Tacrolimus—MTOR—forelimb—peripheral nervous system neoplasm	0.00392	0.157	CbGeAlD
Tacrolimus—PPP3CA—ganglion—peripheral nervous system neoplasm	0.00287	0.115	CbGeAlD
Tacrolimus—ABCA5—trigeminal ganglion—peripheral nervous system neoplasm	0.00209	0.0835	CbGeAlD
Tacrolimus—ABCA5—parotid gland—peripheral nervous system neoplasm	0.00197	0.0787	CbGeAlD
Tacrolimus—PPP3CA—trigeminal ganglion—peripheral nervous system neoplasm	0.00141	0.0564	CbGeAlD
Tacrolimus—PPP3CA—parotid gland—peripheral nervous system neoplasm	0.00133	0.0532	CbGeAlD
Tacrolimus—PPP3CA—brainstem—peripheral nervous system neoplasm	0.00125	0.0499	CbGeAlD
Tacrolimus—FKBP1A—trigeminal ganglion—peripheral nervous system neoplasm	0.000937	0.0375	CbGeAlD
Tacrolimus—MTOR—brainstem—peripheral nervous system neoplasm	0.000922	0.0369	CbGeAlD
Tacrolimus—ABCA5—cerebellum—peripheral nervous system neoplasm	0.000911	0.0364	CbGeAlD
Tacrolimus—Temsirolimus—ABCB1—peripheral nervous system neoplasm	0.000651	0.532	CrCbGaD
Tacrolimus—PPP3CA—cerebellum—peripheral nervous system neoplasm	0.000615	0.0246	CbGeAlD
Tacrolimus—Sirolimus—ABCB1—peripheral nervous system neoplasm	0.000573	0.468	CrCbGaD
Tacrolimus—MTOR—cerebellum—peripheral nervous system neoplasm	0.000454	0.0182	CbGeAlD
Tacrolimus—FKBP1A—cerebellum—peripheral nervous system neoplasm	0.000409	0.0163	CbGeAlD
Tacrolimus—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000217	0.00867	CbGeAlD
Tacrolimus—ABCB1—cerebellum—peripheral nervous system neoplasm	9.45e-05	0.00378	CbGeAlD
Tacrolimus—ALB—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	5.4e-05	0.000856	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.39e-05	0.000855	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—NRAS—peripheral nervous system neoplasm	5.39e-05	0.000855	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPIP5K2—peripheral nervous system neoplasm	5.39e-05	0.000854	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—NRAS—peripheral nervous system neoplasm	5.37e-05	0.000851	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—NRAS—peripheral nervous system neoplasm	5.34e-05	0.000847	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	5.31e-05	0.000842	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	5.31e-05	0.000841	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—peripheral nervous system neoplasm	5.26e-05	0.000834	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—AKT1—peripheral nervous system neoplasm	5.21e-05	0.000826	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	5.19e-05	0.000823	CbGpPWpGaD
Tacrolimus—ALB—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	5.18e-05	0.000822	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by Insulin receptor—HRAS—peripheral nervous system neoplasm	5.15e-05	0.000817	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—AKT1—peripheral nervous system neoplasm	5.08e-05	0.000806	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—AKT1—peripheral nervous system neoplasm	5.04e-05	0.0008	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD34—peripheral nervous system neoplasm	5.03e-05	0.000798	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—NRAS—peripheral nervous system neoplasm	5.02e-05	0.000796	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	5.02e-05	0.000796	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	5.02e-05	0.000796	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—CDKN2A—peripheral nervous system neoplasm	5.02e-05	0.000795	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	4.98e-05	0.000789	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	4.93e-05	0.000782	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—peripheral nervous system neoplasm	4.93e-05	0.000781	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	4.93e-05	0.000781	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	4.92e-05	0.00078	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	4.91e-05	0.000779	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	4.86e-05	0.00077	CbGpPWpGaD
Tacrolimus—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	4.86e-05	0.00077	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	4.85e-05	0.00077	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PPP3R1—peripheral nervous system neoplasm	4.84e-05	0.000768	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.75e-05	0.000752	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.72e-05	0.000748	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	4.71e-05	0.000747	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	4.67e-05	0.00074	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—NRAS—peripheral nervous system neoplasm	4.65e-05	0.000737	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.61e-05	0.000731	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	4.58e-05	0.000726	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.54e-05	0.00072	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	4.5e-05	0.000713	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.48e-05	0.00071	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—NRAS—peripheral nervous system neoplasm	4.48e-05	0.00071	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PPP3R1—peripheral nervous system neoplasm	4.47e-05	0.000709	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	4.45e-05	0.000705	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	4.41e-05	0.000699	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.4e-05	0.000697	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	4.36e-05	0.000692	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PTPN11—peripheral nervous system neoplasm	4.34e-05	0.000687	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	4.34e-05	0.000687	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.29e-05	0.00068	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NCAM1—peripheral nervous system neoplasm	4.28e-05	0.000678	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GNS—peripheral nervous system neoplasm	4.23e-05	0.00067	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.23e-05	0.00067	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	4.22e-05	0.000669	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.18e-05	0.000663	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—peripheral nervous system neoplasm	4.16e-05	0.000659	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	4.15e-05	0.000658	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—CASP3—peripheral nervous system neoplasm	4.08e-05	0.000647	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NME1—peripheral nervous system neoplasm	4.05e-05	0.000642	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.03e-05	0.00064	CbGpPWpGaD
Tacrolimus—Stomatitis—Epirubicin—peripheral nervous system neoplasm	4.03e-05	0.000149	CcSEcCtD
Tacrolimus—Constipation—Etoposide—peripheral nervous system neoplasm	4.02e-05	0.000149	CcSEcCtD
Tacrolimus—Pain—Etoposide—peripheral nervous system neoplasm	4.02e-05	0.000149	CcSEcCtD
Tacrolimus—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000149	CcSEcCtD
Tacrolimus—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000149	CcSEcCtD
Tacrolimus—Dysuria—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000149	CcSEcCtD
Tacrolimus—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000149	CcSEcCtD
Tacrolimus—PPP3CA—Disease—PTPN11—peripheral nervous system neoplasm	4e-05	0.000635	CbGpPWpGaD
Tacrolimus—Dizziness—Alitretinoin—peripheral nervous system neoplasm	3.99e-05	0.000148	CcSEcCtD
Tacrolimus—MTOR—Insulin Signaling—HRAS—peripheral nervous system neoplasm	3.98e-05	0.000632	CbGpPWpGaD
Tacrolimus—Diarrhoea—Vincristine—peripheral nervous system neoplasm	3.97e-05	0.000147	CcSEcCtD
Tacrolimus—MTOR—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	3.96e-05	0.000629	CbGpPWpGaD
Tacrolimus—Sweating—Epirubicin—peripheral nervous system neoplasm	3.96e-05	0.000147	CcSEcCtD
Tacrolimus—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000147	CcSEcCtD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	3.95e-05	0.000625	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	3.95e-05	0.000625	CbGpPWpGaD
Tacrolimus—Haematuria—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000146	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	3.93e-05	0.000622	CbGpPWpGaD
Tacrolimus—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.000145	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000145	CcSEcCtD
Tacrolimus—MTOR—DAP12 signaling—HRAS—peripheral nervous system neoplasm	3.91e-05	0.000619	CbGpPWpGaD
Tacrolimus—Weight increased—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000145	CcSEcCtD
Tacrolimus—Epistaxis—Epirubicin—peripheral nervous system neoplasm	3.9e-05	0.000144	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—COX2—peripheral nervous system neoplasm	3.9e-05	0.000618	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	3.89e-05	0.000617	CbGpPWpGaD
Tacrolimus—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	3.88e-05	0.000144	CcSEcCtD
Tacrolimus—Sinusitis—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000144	CcSEcCtD
Tacrolimus—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	3.88e-05	0.000144	CcSEcCtD
Tacrolimus—MTOR—Disease—ENO2—peripheral nervous system neoplasm	3.87e-05	0.000614	CbGpPWpGaD
Tacrolimus—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000143	CcSEcCtD
Tacrolimus—Nausea—Dactinomycin—peripheral nervous system neoplasm	3.86e-05	0.000143	CcSEcCtD
Tacrolimus—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	3.86e-05	0.000143	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—peripheral nervous system neoplasm	3.85e-05	0.00061	CbGpPWpGaD
Tacrolimus—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	3.85e-05	0.000143	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	3.85e-05	0.000142	CcSEcCtD
Tacrolimus—Dizziness—Vincristine—peripheral nervous system neoplasm	3.84e-05	0.000142	CcSEcCtD
Tacrolimus—Vomiting—Alitretinoin—peripheral nervous system neoplasm	3.83e-05	0.000142	CcSEcCtD
Tacrolimus—MTOR—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	3.83e-05	0.000607	CbGpPWpGaD
Tacrolimus—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.000142	CcSEcCtD
Tacrolimus—Infestation—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.000142	CcSEcCtD
Tacrolimus—Rash—Alitretinoin—peripheral nervous system neoplasm	3.8e-05	0.000141	CcSEcCtD
Tacrolimus—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	3.8e-05	0.000141	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	3.79e-05	0.00014	CcSEcCtD
Tacrolimus—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	3.78e-05	0.00014	CcSEcCtD
Tacrolimus—Bradycardia—Epirubicin—peripheral nervous system neoplasm	3.78e-05	0.00014	CcSEcCtD
Tacrolimus—Headache—Alitretinoin—peripheral nervous system neoplasm	3.78e-05	0.00014	CcSEcCtD
Tacrolimus—Renal failure—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000139	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000139	CcSEcCtD
Tacrolimus—Urticaria—Etoposide—peripheral nervous system neoplasm	3.74e-05	0.000138	CcSEcCtD
Tacrolimus—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000138	CcSEcCtD
Tacrolimus—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000138	CcSEcCtD
Tacrolimus—Jaundice—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000138	CcSEcCtD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	3.72e-05	0.00059	CbGpPWpGaD
Tacrolimus—Rhinitis—Epirubicin—peripheral nervous system neoplasm	3.72e-05	0.000138	CcSEcCtD
Tacrolimus—Abdominal pain—Etoposide—peripheral nervous system neoplasm	3.72e-05	0.000138	CcSEcCtD
Tacrolimus—Body temperature increased—Etoposide—peripheral nervous system neoplasm	3.72e-05	0.000138	CcSEcCtD
Tacrolimus—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000138	CcSEcCtD
Tacrolimus—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000138	CcSEcCtD
Tacrolimus—Hepatitis—Epirubicin—peripheral nervous system neoplasm	3.71e-05	0.000137	CcSEcCtD
Tacrolimus—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	3.71e-05	0.000137	CcSEcCtD
Tacrolimus—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	3.69e-05	0.000137	CcSEcCtD
Tacrolimus—Vomiting—Vincristine—peripheral nervous system neoplasm	3.69e-05	0.000137	CcSEcCtD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	3.69e-05	0.000584	CbGpPWpGaD
Tacrolimus—Asthenia—Cisplatin—peripheral nervous system neoplasm	3.68e-05	0.000136	CcSEcCtD
Tacrolimus—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	3.68e-05	0.000136	CcSEcCtD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	3.68e-05	0.000583	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	3.68e-05	0.000583	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—HRAS—peripheral nervous system neoplasm	3.68e-05	0.000583	CbGpPWpGaD
Tacrolimus—Sweating—Doxorubicin—peripheral nervous system neoplasm	3.67e-05	0.000136	CcSEcCtD
Tacrolimus—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	3.67e-05	0.000136	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	3.67e-05	0.000581	CbGpPWpGaD
Tacrolimus—Rash—Vincristine—peripheral nervous system neoplasm	3.66e-05	0.000136	CcSEcCtD
Tacrolimus—Dermatitis—Vincristine—peripheral nervous system neoplasm	3.66e-05	0.000135	CcSEcCtD
Tacrolimus—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	3.66e-05	0.000135	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—peripheral nervous system neoplasm	3.65e-05	0.000135	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	3.65e-05	0.000135	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	3.64e-05	0.000577	CbGpPWpGaD
Tacrolimus—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000135	CcSEcCtD
Tacrolimus—ALB—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.64e-05	0.000577	CbGpPWpGaD
Tacrolimus—Headache—Vincristine—peripheral nervous system neoplasm	3.64e-05	0.000135	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000134	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	3.61e-05	0.000572	CbGpPWpGaD
Tacrolimus—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000134	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	3.59e-05	0.00057	CbGpPWpGaD
Tacrolimus—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000133	CcSEcCtD
Tacrolimus—Nausea—Alitretinoin—peripheral nervous system neoplasm	3.58e-05	0.000133	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—peripheral nervous system neoplasm	3.58e-05	0.000132	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.58e-05	0.000567	CbGpPWpGaD
Tacrolimus—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	3.57e-05	0.000132	CcSEcCtD
Tacrolimus—MTOR—Insulin Signaling—AKT1—peripheral nervous system neoplasm	3.52e-05	0.000558	CbGpPWpGaD
Tacrolimus—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	3.51e-05	0.00013	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.00013	CcSEcCtD
Tacrolimus—MTOR—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	3.5e-05	0.000555	CbGpPWpGaD
Tacrolimus—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	3.5e-05	0.000129	CcSEcCtD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	3.48e-05	0.000552	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	3.48e-05	0.000552	CbGpPWpGaD
Tacrolimus—Eye disorder—Epirubicin—peripheral nervous system neoplasm	3.47e-05	0.000128	CcSEcCtD
Tacrolimus—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	3.47e-05	0.000128	CcSEcCtD
Tacrolimus—MTOR—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	3.47e-05	0.00055	CbGpPWpGaD
Tacrolimus—Tinnitus—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000128	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000128	CcSEcCtD
Tacrolimus—Nausea—Vincristine—peripheral nervous system neoplasm	3.45e-05	0.000128	CcSEcCtD
Tacrolimus—MTOR—DAP12 signaling—AKT1—peripheral nervous system neoplasm	3.45e-05	0.000547	CbGpPWpGaD
Tacrolimus—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	3.45e-05	0.000128	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—peripheral nervous system neoplasm	3.45e-05	0.000128	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	3.44e-05	0.000128	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	3.43e-05	0.000127	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	3.43e-05	0.000127	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—ERBB2—peripheral nervous system neoplasm	3.43e-05	0.000543	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—NRAS—peripheral nervous system neoplasm	3.42e-05	0.000543	CbGpPWpGaD
Tacrolimus—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	3.42e-05	0.000127	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	3.41e-05	0.000126	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.41e-05	0.00054	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—HRAS—peripheral nervous system neoplasm	3.4e-05	0.000539	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—peripheral nervous system neoplasm	3.4e-05	0.000539	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.39e-05	0.000538	CbGpPWpGaD
Tacrolimus—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	3.39e-05	0.000126	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000125	CcSEcCtD
Tacrolimus—Asthenia—Etoposide—peripheral nervous system neoplasm	3.38e-05	0.000125	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000125	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—peripheral nervous system neoplasm	3.37e-05	0.000125	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000125	CcSEcCtD
Tacrolimus—MTOR—Immune System—IFNB1—peripheral nervous system neoplasm	3.36e-05	0.000532	CbGpPWpGaD
Tacrolimus—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	3.35e-05	0.000124	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	3.35e-05	0.000124	CcSEcCtD
Tacrolimus—Chills—Epirubicin—peripheral nervous system neoplasm	3.33e-05	0.000123	CcSEcCtD
Tacrolimus—Pruritus—Etoposide—peripheral nervous system neoplasm	3.33e-05	0.000123	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	3.32e-05	0.000123	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	3.31e-05	0.000123	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.000121	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.27e-05	0.000519	CbGpPWpGaD
Tacrolimus—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.27e-05	0.000121	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	3.26e-05	0.000516	CbGpPWpGaD
Tacrolimus—Mental disorder—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.00012	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.00012	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—PTPN11—peripheral nervous system neoplasm	3.25e-05	0.000515	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	3.25e-05	0.000514	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—AKT1—peripheral nervous system neoplasm	3.25e-05	0.000514	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	3.25e-05	0.000514	CbGpPWpGaD
Tacrolimus—Rash—Cisplatin—peripheral nervous system neoplasm	3.24e-05	0.00012	CcSEcCtD
Tacrolimus—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.24e-05	0.00012	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.00012	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.00012	CcSEcCtD
Tacrolimus—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.22e-05	0.000119	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	3.22e-05	0.00051	CbGpPWpGaD
Tacrolimus—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000119	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	3.2e-05	0.000119	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.19e-05	0.000505	CbGpPWpGaD
Tacrolimus—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	3.19e-05	0.000118	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—peripheral nervous system neoplasm	3.19e-05	0.000118	CcSEcCtD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	3.19e-05	0.000505	CbGpPWpGaD
Tacrolimus—Flatulence—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000118	CcSEcCtD
Tacrolimus—MTOR—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	3.17e-05	0.000503	CbGpPWpGaD
Tacrolimus—Tension—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.000117	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	3.16e-05	0.000117	CcSEcCtD
Tacrolimus—PPP3CA—Disease—ERBB2—peripheral nervous system neoplasm	3.16e-05	0.000502	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IFNB1—peripheral nervous system neoplasm	3.15e-05	0.000499	CbGpPWpGaD
Tacrolimus—Nervousness—Epirubicin—peripheral nervous system neoplasm	3.14e-05	0.000116	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.13e-05	0.000496	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.13e-05	0.000496	CbGpPWpGaD
Tacrolimus—Back pain—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000116	CcSEcCtD
Tacrolimus—MTOR—Disease—SLC2A1—peripheral nervous system neoplasm	3.12e-05	0.000495	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PTPN11—peripheral nervous system neoplasm	3.12e-05	0.000494	CbGpPWpGaD
Tacrolimus—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	3.12e-05	0.000115	CcSEcCtD
Tacrolimus—Dizziness—Etoposide—peripheral nervous system neoplasm	3.11e-05	0.000115	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	3.11e-05	0.000115	CcSEcCtD
Tacrolimus—FKBP1A—Disease—PTPN11—peripheral nervous system neoplasm	3.1e-05	0.000492	CbGpPWpGaD
Tacrolimus—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	3.1e-05	0.000115	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.1e-05	0.000115	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—peripheral nervous system neoplasm	3.08e-05	0.000114	CcSEcCtD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	3.08e-05	0.000488	CbGpPWpGaD
Tacrolimus—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	3.07e-05	0.000114	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	3.05e-05	0.000484	CbGpPWpGaD
Tacrolimus—Nausea—Cisplatin—peripheral nervous system neoplasm	3.05e-05	0.000113	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—peripheral nervous system neoplasm	3.05e-05	0.000113	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—peripheral nervous system neoplasm	3.04e-05	0.000112	CcSEcCtD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.02e-05	0.000479	CbGpPWpGaD
Tacrolimus—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	3.01e-05	0.000111	CcSEcCtD
Tacrolimus—MTOR—B Cell Activation—AKT1—peripheral nervous system neoplasm	3e-05	0.000476	CbGpPWpGaD
Tacrolimus—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000111	CcSEcCtD
Tacrolimus—Vomiting—Etoposide—peripheral nervous system neoplasm	2.99e-05	0.000111	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000111	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000111	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—peripheral nervous system neoplasm	2.99e-05	0.000111	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—peripheral nervous system neoplasm	2.97e-05	0.00011	CcSEcCtD
Tacrolimus—Rash—Etoposide—peripheral nervous system neoplasm	2.97e-05	0.00011	CcSEcCtD
Tacrolimus—Dermatitis—Etoposide—peripheral nervous system neoplasm	2.96e-05	0.00011	CcSEcCtD
Tacrolimus—Headache—Etoposide—peripheral nervous system neoplasm	2.95e-05	0.000109	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000109	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—peripheral nervous system neoplasm	2.93e-05	0.000109	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	2.93e-05	0.000464	CbGpPWpGaD
Tacrolimus—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	2.93e-05	0.000108	CcSEcCtD
Tacrolimus—ALB—Hemostasis—KNG1—peripheral nervous system neoplasm	2.92e-05	0.000462	CbGpPWpGaD
Tacrolimus—Malaise—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000108	CcSEcCtD
Tacrolimus—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.91e-05	0.000461	CbGpPWpGaD
Tacrolimus—Nervousness—Doxorubicin—peripheral nervous system neoplasm	2.9e-05	0.000108	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—peripheral nervous system neoplasm	2.9e-05	0.000108	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—peripheral nervous system neoplasm	2.9e-05	0.000107	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—peripheral nervous system neoplasm	2.89e-05	0.000107	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000107	CcSEcCtD
Tacrolimus—PPP3CA—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.89e-05	0.000458	CbGpPWpGaD
Tacrolimus—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	2.87e-05	0.000106	CcSEcCtD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	2.87e-05	0.000456	CbGpPWpGaD
Tacrolimus—Palpitations—Epirubicin—peripheral nervous system neoplasm	2.86e-05	0.000106	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.85e-05	0.000452	CbGpPWpGaD
Tacrolimus—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	2.84e-05	0.000105	CcSEcCtD
Tacrolimus—Cough—Epirubicin—peripheral nervous system neoplasm	2.82e-05	0.000104	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	2.82e-05	0.000447	CbGpPWpGaD
Tacrolimus—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	2.82e-05	0.000104	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.8e-05	0.000444	CbGpPWpGaD
Tacrolimus—Convulsion—Epirubicin—peripheral nervous system neoplasm	2.8e-05	0.000104	CcSEcCtD
Tacrolimus—Nausea—Etoposide—peripheral nervous system neoplasm	2.79e-05	0.000103	CcSEcCtD
Tacrolimus—MTOR—Cellular responses to stress—TP53—peripheral nervous system neoplasm	2.79e-05	0.000442	CbGpPWpGaD
Tacrolimus—Hypertension—Epirubicin—peripheral nervous system neoplasm	2.79e-05	0.000103	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	0.000103	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.000102	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—peripheral nervous system neoplasm	2.75e-05	0.000102	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—peripheral nervous system neoplasm	2.75e-05	0.000102	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—peripheral nervous system neoplasm	2.75e-05	0.000102	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—peripheral nervous system neoplasm	2.75e-05	0.000102	CcSEcCtD
Tacrolimus—ALB—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.74e-05	0.000435	CbGpPWpGaD
Tacrolimus—Anxiety—Epirubicin—peripheral nervous system neoplasm	2.74e-05	0.000102	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	2.73e-05	0.000101	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000101	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	9.98e-05	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—peripheral nervous system neoplasm	2.69e-05	9.96e-05	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—peripheral nervous system neoplasm	2.69e-05	9.95e-05	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—peripheral nervous system neoplasm	2.68e-05	9.93e-05	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	2.68e-05	9.91e-05	CcSEcCtD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.67e-05	0.000424	CbGpPWpGaD
Tacrolimus—Confusional state—Epirubicin—peripheral nervous system neoplasm	2.66e-05	9.85e-05	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	9.78e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	2.64e-05	9.77e-05	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—peripheral nervous system neoplasm	2.64e-05	9.77e-05	CcSEcCtD
Tacrolimus—ALB—Metabolism—GNS—peripheral nervous system neoplasm	2.63e-05	0.000417	CbGpPWpGaD
Tacrolimus—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	2.63e-05	9.73e-05	CcSEcCtD
Tacrolimus—Infection—Epirubicin—peripheral nervous system neoplasm	2.62e-05	9.7e-05	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—peripheral nervous system neoplasm	2.61e-05	9.66e-05	CcSEcCtD
Tacrolimus—PPP3CA—Immune System—NRAS—peripheral nervous system neoplasm	2.61e-05	0.000413	CbGpPWpGaD
Tacrolimus—Shock—Epirubicin—peripheral nervous system neoplasm	2.59e-05	9.61e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—HGF—peripheral nervous system neoplasm	2.59e-05	0.000411	CbGpPWpGaD
Tacrolimus—Convulsion—Doxorubicin—peripheral nervous system neoplasm	2.59e-05	9.59e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	2.59e-05	9.58e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	2.58e-05	9.56e-05	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—peripheral nervous system neoplasm	2.58e-05	9.56e-05	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—peripheral nervous system neoplasm	2.57e-05	9.53e-05	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—ERBB2—peripheral nervous system neoplasm	2.57e-05	0.000407	CbGpPWpGaD
Tacrolimus—Skin disorder—Epirubicin—peripheral nervous system neoplasm	2.56e-05	9.49e-05	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—ENO2—peripheral nervous system neoplasm	2.56e-05	0.000406	CbGpPWpGaD
Tacrolimus—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.55e-05	9.44e-05	CcSEcCtD
Tacrolimus—ALB—Hemostasis—GNAS—peripheral nervous system neoplasm	2.55e-05	0.000404	CbGpPWpGaD
Tacrolimus—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	9.43e-05	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	9.43e-05	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	9.43e-05	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—peripheral nervous system neoplasm	2.54e-05	9.39e-05	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	2.53e-05	9.36e-05	CcSEcCtD
Tacrolimus—ALB—Metabolism—NME1—peripheral nervous system neoplasm	2.52e-05	0.0004	CbGpPWpGaD
Tacrolimus—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.52e-05	9.31e-05	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.51e-05	9.31e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling by NGF—HRAS—peripheral nervous system neoplasm	2.5e-05	0.000397	CbGpPWpGaD
Tacrolimus—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.49e-05	9.22e-05	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.46e-05	9.13e-05	CcSEcCtD
Tacrolimus—MTOR—Adaptive Immune System—ERBB2—peripheral nervous system neoplasm	2.46e-05	0.000391	CbGpPWpGaD
Tacrolimus—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.46e-05	9.11e-05	CcSEcCtD
Tacrolimus—FKBP1A—Disease—ERBB2—peripheral nervous system neoplasm	2.45e-05	0.000389	CbGpPWpGaD
Tacrolimus—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.44e-05	9.04e-05	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	2.44e-05	9.04e-05	CcSEcCtD
Tacrolimus—ALB—Hemostasis—HGF—peripheral nervous system neoplasm	2.43e-05	0.000385	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.43e-05	0.000385	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—COX2—peripheral nervous system neoplasm	2.43e-05	0.000385	CbGpPWpGaD
Tacrolimus—Infection—Doxorubicin—peripheral nervous system neoplasm	2.42e-05	8.98e-05	CcSEcCtD
Tacrolimus—PPP3CA—Disease—NRAS—peripheral nervous system neoplasm	2.41e-05	0.000382	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.4e-05	0.000381	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.4e-05	8.9e-05	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	8.89e-05	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.39e-05	8.86e-05	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.39e-05	8.85e-05	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.39e-05	8.83e-05	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	2.38e-05	8.82e-05	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.37e-05	8.78e-05	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.37e-05	8.77e-05	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.36e-05	8.74e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.35e-05	0.000373	CbGpPWpGaD
Tacrolimus—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.35e-05	8.71e-05	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—peripheral nervous system neoplasm	2.34e-05	8.68e-05	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	8.61e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.32e-05	8.6e-05	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	2.31e-05	0.000365	CbGpPWpGaD
Tacrolimus—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.29e-05	8.49e-05	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—peripheral nervous system neoplasm	2.28e-05	8.44e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	2.28e-05	8.43e-05	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.27e-05	8.42e-05	CcSEcCtD
Tacrolimus—Pain—Epirubicin—peripheral nervous system neoplasm	2.26e-05	8.35e-05	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—peripheral nervous system neoplasm	2.26e-05	8.35e-05	CcSEcCtD
Tacrolimus—PPP3CA—Disease—MYC—peripheral nervous system neoplasm	2.24e-05	0.000355	CbGpPWpGaD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	2.22e-05	8.23e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.22e-05	0.000351	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—AKT1—peripheral nervous system neoplasm	2.21e-05	0.00035	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	2.21e-05	0.00035	CbGpPWpGaD
Tacrolimus—Insomnia—Doxorubicin—peripheral nervous system neoplasm	2.21e-05	8.17e-05	CcSEcCtD
Tacrolimus—ALB—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.21e-05	0.00035	CbGpPWpGaD
Tacrolimus—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.19e-05	8.11e-05	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.18e-05	8.06e-05	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.17e-05	0.000345	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.17e-05	8.05e-05	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.17e-05	8.03e-05	CcSEcCtD
Tacrolimus—ALB—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.17e-05	0.000343	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—BCHE—peripheral nervous system neoplasm	2.16e-05	0.000343	CbGpPWpGaD
Tacrolimus—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.16e-05	7.99e-05	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.15e-05	7.95e-05	CcSEcCtD
Tacrolimus—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	2.13e-05	0.000337	CbGpPWpGaD
Tacrolimus—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	7.85e-05	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.11e-05	7.8e-05	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.1e-05	7.79e-05	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.1e-05	7.76e-05	CcSEcCtD
Tacrolimus—PPP3CA—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.09e-05	0.000331	CbGpPWpGaD
Tacrolimus—Pain—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	7.73e-05	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	7.73e-05	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.08e-05	7.72e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	2.08e-05	7.72e-05	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.06e-05	0.000327	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TH—peripheral nervous system neoplasm	2.03e-05	0.000322	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.01e-05	0.000319	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.01e-05	0.000319	CbGpPWpGaD
Tacrolimus—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.01e-05	7.45e-05	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2e-05	7.39e-05	CcSEcCtD
Tacrolimus—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.96e-05	0.000311	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—peripheral nervous system neoplasm	1.95e-05	0.000309	CbGpPWpGaD
Tacrolimus—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.94e-05	7.19e-05	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	7.18e-05	CcSEcCtD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.93e-05	0.000307	CbGpPWpGaD
Tacrolimus—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	7.14e-05	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	7.14e-05	CcSEcCtD
Tacrolimus—MTOR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.92e-05	0.000304	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—peripheral nervous system neoplasm	1.91e-05	0.000302	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.9e-05	0.000301	CbGpPWpGaD
Tacrolimus—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.89e-05	7.01e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—PTPN11—peripheral nervous system neoplasm	1.89e-05	0.0003	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—peripheral nervous system neoplasm	1.87e-05	0.000297	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—peripheral nervous system neoplasm	1.87e-05	0.000296	CbGpPWpGaD
Tacrolimus—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.87e-05	6.91e-05	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	1.85e-05	0.000293	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.84e-05	0.000292	CbGpPWpGaD
Tacrolimus—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.8e-05	6.68e-05	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.8e-05	6.66e-05	CcSEcCtD
Tacrolimus—ALB—Hemostasis—PTPN11—peripheral nervous system neoplasm	1.77e-05	0.000281	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—peripheral nervous system neoplasm	1.76e-05	0.000279	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.76e-05	0.000279	CbGpPWpGaD
Tacrolimus—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.75e-05	6.48e-05	CcSEcCtD
Tacrolimus—MTOR—Disease—PTPN11—peripheral nervous system neoplasm	1.75e-05	0.000277	CbGpPWpGaD
Tacrolimus—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.74e-05	6.46e-05	CcSEcCtD
Tacrolimus—FKBP1A—Disease—MYC—peripheral nervous system neoplasm	1.74e-05	0.000276	CbGpPWpGaD
Tacrolimus—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.73e-05	6.39e-05	CcSEcCtD
Tacrolimus—FKBP1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.72e-05	0.000272	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.69e-05	0.000267	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000267	CbGpPWpGaD
Tacrolimus—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.68e-05	6.21e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.67e-05	6.18e-05	CcSEcCtD
Tacrolimus—Rash—Epirubicin—peripheral nervous system neoplasm	1.66e-05	6.16e-05	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.66e-05	6.15e-05	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—GNAS—peripheral nervous system neoplasm	1.66e-05	0.000263	CbGpPWpGaD
Tacrolimus—Headache—Epirubicin—peripheral nervous system neoplasm	1.65e-05	6.12e-05	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—ABCB1—peripheral nervous system neoplasm	1.63e-05	0.000258	CbGpPWpGaD
Tacrolimus—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.61e-05	5.98e-05	CcSEcCtD
Tacrolimus—ALB—Metabolism—ENO2—peripheral nervous system neoplasm	1.59e-05	0.000253	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.57e-05	0.000249	CbGpPWpGaD
Tacrolimus—Nausea—Epirubicin—peripheral nervous system neoplasm	1.57e-05	5.8e-05	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	1.56e-05	0.000248	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.56e-05	0.000247	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.56e-05	0.000247	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—peripheral nervous system neoplasm	1.55e-05	0.000246	CbGpPWpGaD
Tacrolimus—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.55e-05	5.75e-05	CcSEcCtD
Tacrolimus—Rash—Doxorubicin—peripheral nervous system neoplasm	1.54e-05	5.7e-05	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.54e-05	5.69e-05	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—peripheral nervous system neoplasm	1.53e-05	5.66e-05	CcSEcCtD
Tacrolimus—MTOR—Immune System—ERBB2—peripheral nervous system neoplasm	1.49e-05	0.000237	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.49e-05	0.000236	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	1.47e-05	0.000233	CbGpPWpGaD
Tacrolimus—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.45e-05	5.37e-05	CcSEcCtD
Tacrolimus—MTOR—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.43e-05	0.000226	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.42e-05	0.000225	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.4e-05	0.000221	CbGpPWpGaD
Tacrolimus—MTOR—Disease—ERBB2—peripheral nervous system neoplasm	1.38e-05	0.000219	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.37e-05	0.000217	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—peripheral nervous system neoplasm	1.37e-05	0.000216	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.36e-05	0.000216	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—BCHE—peripheral nervous system neoplasm	1.35e-05	0.000214	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000212	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.31e-05	0.000208	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.31e-05	0.000208	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.31e-05	0.000207	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.29e-05	0.000204	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.28e-05	0.000204	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TH—peripheral nervous system neoplasm	1.27e-05	0.000201	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.26e-05	0.0002	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.23e-05	0.000195	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.22e-05	0.000194	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.22e-05	0.000193	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.21e-05	0.000192	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—peripheral nervous system neoplasm	1.21e-05	0.000191	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	1.2e-05	0.00019	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.18e-05	0.000187	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	1.18e-05	0.000187	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—peripheral nervous system neoplasm	1.14e-05	0.00018	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.13e-05	0.000178	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.11e-05	0.000176	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.09e-05	0.000173	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—peripheral nervous system neoplasm	1.07e-05	0.000169	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—peripheral nervous system neoplasm	1.05e-05	0.000166	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GNAS—peripheral nervous system neoplasm	1.03e-05	0.000164	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ABCB1—peripheral nervous system neoplasm	1.01e-05	0.000161	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1e-05	0.000158	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—peripheral nervous system neoplasm	9.78e-06	0.000155	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.66e-06	0.000153	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.56e-06	0.000152	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	9.06e-06	0.000144	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.77e-06	0.000139	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	8.6e-06	0.000136	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.44e-06	0.000134	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—peripheral nervous system neoplasm	8.32e-06	0.000132	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—peripheral nervous system neoplasm	8.15e-06	0.000129	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—peripheral nervous system neoplasm	7.79e-06	0.000124	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—peripheral nervous system neoplasm	7.68e-06	0.000122	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.35e-06	0.000117	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—peripheral nervous system neoplasm	7.34e-06	0.000116	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	7.27e-06	0.000115	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.94e-06	0.00011	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—peripheral nervous system neoplasm	6.88e-06	0.000109	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.85e-06	0.000109	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.84e-06	0.000108	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—peripheral nervous system neoplasm	6.78e-06	0.000107	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.62e-06	8.91e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.58e-06	8.85e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.48e-06	8.68e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.38e-06	8.53e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.75e-06	7.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	4.48e-06	7.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	3.24e-06	5.14e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—peripheral nervous system neoplasm	2.79e-06	4.42e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.44e-06	3.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.51e-06	2.39e-05	CbGpPWpGaD
